- Home
- PRME vs TERN Comparison
PRME vs TERN Comparison
Compare PRME & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- TERN
- Stock Information
- Founded
- PRME 2019
- TERN 2017
- Country
- PRME United States
- TERN United States
- Employees
- PRME N/A
- TERN N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- TERN Health Care
- Exchange
- PRME Nasdaq
- TERN Nasdaq
- Market Cap
- PRME 693.5M
- TERN 634.5M
- IPO Year
- PRME 2022
- TERN 2021
- Fundamental
- Price
- PRME $4.67
- TERN $7.30
- Analyst Decision
- PRME Buy
- TERN Buy
- Analyst Count
- PRME 6
- TERN 6
- Target Price
- PRME $8.88
- TERN $13.99
- AVG Volume (30 Days)
- PRME 2.9M
- TERN 1.1M
- Earning Date
- PRME 11-11-2025
- TERN 11-11-2025
- Dividend Yield
- PRME N/A
- TERN N/A
- EPS Growth
- PRME N/A
- TERN N/A
- EPS
- PRME N/A
- TERN N/A
- Revenue
- PRME $4,961,000.00
- TERN N/A
- Revenue This Year
- PRME $179.58
- TERN N/A
- Revenue Next Year
- PRME N/A
- TERN N/A
- P/E Ratio
- PRME N/A
- TERN N/A
- Revenue Growth
- PRME 739.42
- TERN N/A
- 52 Week Low
- PRME $1.11
- TERN $1.87
- 52 Week High
- PRME $5.17
- TERN $10.70
- Technical
- Relative Strength Index (RSI)
- PRME 67.60
- TERN 52.85
- Support Level
- PRME $3.09
- TERN N/A
- Resistance Level
- PRME $4.18
- TERN $7.67
- Average True Range (ATR)
- PRME 0.31
- TERN 0.41
- MACD
- PRME 0.11
- TERN -0.32
- Stochastic Oscillator
- PRME 98.14
- TERN 93.83
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.